Origin Agritech Limited Q4 FY2024 earnings call

• New CEO Weibin Yan outlined a 3-phase strategy: 2024-2026 focus on stabilization, achieving cash flow breakeven, and optimizing operations; by 2027, aim to be one of China's six leading corn companies; by 2030-2032, target to be one of China's top five corn seed companies and a leading global biotech seed company with 20% revenue from overseas.
• Achievements in 2024 include GMO safety certificate for BBL2-2 transgenic maize, breakthrough in induction line gene editing technology, and establishment of the Origin Marker Biological Breeding Service Consortium.
• Xinjiang production facility with 4,000 hectares fixed plantation and 75,000 tons annual processing capacity. 8 new varieties set to launch in 2025.
• CFO Patrick Cheng discussed financial results, R&D investment, liquidity position, and financial strategies aligned with the 3-phase plan, including focus on cash flow breakeven, profitable growth through biotech commercialization, and building a sustainable profitable model.

In Fiscal Year 2024, Origin Agritech achieved revenue of $16.2 million, representing a 24.6% increase from $13 million in Fiscal Year 2023. This growth was primarily driven by higher volume of corn seed sales. General and administrative expenses rose to $5.1 million from $1.99 million. R&D investment increased to $1.5 million from $1 million. Net income from continuing operations was $2.7 million, lower than the $8.7 million in Fiscal Year 2023. Net income attributable to Origin was $3 million compared to $7.7 million in the prior year.

• Near term: Focus on achieving cash flow breakeven while maintaining investment in R&D and operational improvements.
• Medium term: Drive profitable growth through commercialization of biotech innovation and seed business expansion, expecting improving margins as operations scale.
• Long term: Build a sustainable, profitable business model combining stable seed revenues with high-margin biotech licensing and service fees. New varieties in 2025 expected to contribute to revenue and profitability.

• Failure to develop and market new products and optimally manage product life cycles.
• Ability to respond to market acceptance, rules, regulations, and policies affecting products.
• Failure to appropriately manage process safety and product stewardship issues.
• Changes in laws, regulations, or political conditions.
• Global economic and capital markets conditions, business or supply disruptions, natural disasters, and weather events.
• Ability to protect and enforce intellectual property rights.
• Separation of underperforming or non-strategic assets or businesses.

Q: Why has the gross margin in the past two years been significantly lower than in the early 2000s?

A: The difference reflects industry evolution and strategic positioning. Initiatives like BBL2-2 GMO corn varieties, gene-editing breakthrough, and modernizing Xinjiang facility are expected to drive margin expansion.

Q: Is the company on track to meet revenue forecast shared in June 2024?

A: Under new management, a comprehensive eight-year strategy roadmap is in place, focusing on building a sustainable foundation rather than short-term targets. Investors should evaluate execution of the strategic roadmap.

Q: Will you consider changing the fiscal year to a calendar year?

A: The company is evaluating reporting optimizations, including potential change to calendar year, but transition requires careful planning to ensure compliance with regulations.

Q: What plans do you have to scale up NEC to meet demand like Muyuan?

A: Xinjiang facility has capacity to meet demand, with 4,000 hectares plantation and 75,000 tons annual processing capacity. Prioritization on biotechnology commercialization and seed business expansion.

Q: How does gene editing breakthrough translate to commercial value?

A: Allows precise genetic modifications in one year vs 3-4 years traditionally, enabling faster and cheaper development of improved varieties, and partnering with operating companies.

Q: What differentiates Origin from other agricultural biotechnology companies in China?

A: Unique advantages include both GMO and gene editing capabilities, end-to-end capabilities from research to production, extensive Germplasm Bank and breeding programs, and state-of-the-art Xinjiang facility.

Q: What gives confidence to achieve the eight-year strategy?

A: Advantages include GMO safety certificate for BBL2-2 corn, gene editing platform, service consortium generating revenue, seed platform reputation, and new management team with industry expertise.

Q: How do you see the Chinese agricultural biotechnology market evolving?

A: China is at an inflection point with government support for GMO commercialization. Origin is well-positioned with GMO trait, gene editing capabilities, and production facilities, giving first-mover advantage.